214 related articles for article (PubMed ID: 30345829)
1. Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives.
Tsiakanikas P; Giaginis C; Kontos CK; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):981-991. PubMed ID: 30345829
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers.
Fedorko M; Pacik D; Wasserbauer R; Juracek J; Varga G; Ghazal M; Nussir MI
Int J Biol Markers; 2016 Feb; 31(1):e26-37. PubMed ID: 26481440
[TBL] [Abstract][Full Text] [Related]
3. The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma.
He YH; Chen C; Shi Z
J Cell Physiol; 2018 Jun; 233(6):4458-4465. PubMed ID: 29215721
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in Renal Cell Carcinoma.
Sellitti DF; Doi SQ
Microrna; 2015; 4(1):26-35. PubMed ID: 26165467
[TBL] [Abstract][Full Text] [Related]
6. Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
Semeniuk-Wojtaś A; Stec R; Szczylik C
Urol Oncol; 2016 May; 34(5):215-20. PubMed ID: 26850779
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Kovacova J; Poprach A; Buchler T; Cho WC; Slaby O
Clin Chem Lab Med; 2018 Aug; 56(9):1426-1431. PubMed ID: 29451857
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.
Gu L; Li H; Chen L; Ma X; Gao Y; Li X; Zhang Y; Fan Y; Zhang X
Oncotarget; 2015 Oct; 6(32):32545-60. PubMed ID: 26416448
[TBL] [Abstract][Full Text] [Related]
10. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma.
Khella HW; Bakhet M; Allo G; Jewett MA; Girgis AH; Latif A; Girgis H; Von Both I; Bjarnason GA; Yousef GM
Carcinogenesis; 2013 Oct; 34(10):2231-9. PubMed ID: 23715501
[TBL] [Abstract][Full Text] [Related]
11. miRNAs as potential regulators of mTOR pathway in renal cell carcinoma.
Nogueira I; Dias F; Teixeira AL; Medeiros R
Pharmacogenomics; 2018 Feb; 19(3):249-261. PubMed ID: 29334302
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA expression profiling of Xp11 renal cell carcinoma.
Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
[TBL] [Abstract][Full Text] [Related]
13. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC.
Szabó Z; Szegedi K; Gombos K; Mahua C; Flaskó T; Harda K; Halmos G
Urol Oncol; 2016 Dec; 34(12):533.e21-533.e27. PubMed ID: 27427222
[TBL] [Abstract][Full Text] [Related]
14. Prognostic signatures for renal cancer as identified by long non-coding and miRNA competing endogenous network analysis.
Gao H; Chen X; Shang Z; Niu Y
Oncol Rep; 2018 Aug; 40(2):959-967. PubMed ID: 29901101
[TBL] [Abstract][Full Text] [Related]
15. The complex roles of microRNAs in the metastasis of renal cell carcinoma.
Zhang L; Xul B; Chen S; Lu K; Liu C; Wang Y; Zhao Y; Zhang X; Liu D; Chen M
J Nanosci Nanotechnol; 2013 May; 13(5):3195-203. PubMed ID: 23858831
[TBL] [Abstract][Full Text] [Related]
16. A Review of Recent Research on the Role of MicroRNAs in Renal Cancer.
Yang L; Zou X; Zou J; Zhang G
Med Sci Monit; 2021 May; 27():e930639. PubMed ID: 33963171
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
Tusong H; Maolakuerban N; Guan J; Rexiati M; Wang WG; Azhati B; Nuerrula Y; Wang YJ
Cancer Biomark; 2017; 18(1):79-85. PubMed ID: 27814278
[TBL] [Abstract][Full Text] [Related]
18. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.
Heinemann FG; Tolkach Y; Deng M; Schmidt D; Perner S; Kristiansen G; Müller SC; Ellinger J
Clin Epigenetics; 2018; 10():11. PubMed ID: 29410711
[TBL] [Abstract][Full Text] [Related]
19. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.
Pan X; Quan J; Li Z; Zhao L; Zhou L; Jinling X; Weijie X; Guan X; Li H; Yang S; Gui Y; Lai Y
Biomed Pharmacother; 2018 Jun; 102():718-727. PubMed ID: 29604591
[TBL] [Abstract][Full Text] [Related]
20. microRNA‑572 functions as an oncogene and a potential biomarker for renal cell carcinoma prognosis.
Pan X; Li Z; Zhao L; Quan J; Zhou L; Xu J; Xu W; Guan X; Li H; Yang S; Gui Y; Lai Y
Oncol Rep; 2018 Nov; 40(5):3092-3101. PubMed ID: 30132566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
